Zhejiang Ausun Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Zhejiang Ausun Pharmaceutical Co., Ltd. carries a market capitalization of 7.04B, placing it among publicly traded companies globally. Its enterprise value stands at 6.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.04B |
| Enterprise Value | 6.60B |
Share Statistics
Zhejiang Ausun Pharmaceutical Co., Ltd. currently has 830.30M shares outstanding.
| Shares Outstanding | 830.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Zhejiang Ausun Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 37.82. The price-to-sales ratio is 9.46, and the price-to-book ratio stands at 3.97.
| PE Ratio | 37.82 |
| PS Ratio | 9.46 |
| PB Ratio | 3.97 |
| P/TBV Ratio | 3.27 |
| P/FCF Ratio | 67.40 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Zhejiang Ausun Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 36.36 and an EV/FCF ratio of 56.56. The EV/Sales ratio of 8.42 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 36.36 provides insight into valuation relative to core operating earnings.
| EV / Sales | 8.42 |
| EV / EBITDA | 36.36 |
| EV / EBIT | 36.36 |
| EV / FCF | 56.56 |
Financial Position
Zhejiang Ausun Pharmaceutical Co., Ltd. maintains a current ratio of 2.83, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.67, indicating elevated leverage, while an interest coverage ratio of 23.71 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.83 |
| Quick Ratio | 1.75 |
| Debt / Equity | 13.67 |
| Debt / EBITDA | 1.82 |
| Interest Coverage | 23.71 |
Financial Efficiency
Zhejiang Ausun Pharmaceutical Co., Ltd. posts a return on equity of 11.51 and a return on invested capital of 5.94.
| Return on Equity (ROE) | 11.51 |
| Return on Assets (ROA) | 6.42 |
| Return on Invested Capital (ROIC) | 5.94 |
| Return on Capital Employed (ROCE) | 10.28 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.96 |
Taxes
Over the trailing twelve months, Zhejiang Ausun Pharmaceutical Co., Ltd. has paid 31.00M in income taxes, reflecting an effective tax rate of 13.64.
| Income Tax | 31.00M |
| Effective Tax Rate | 13.64 |
Stock Price Statistics
Zhejiang Ausun Pharmaceutical Co., Ltd.'s stock has declined approximately -6.40177% over the past 52 weeks. The 50-day moving average sits at 9.33, while the 200-day moving average is 9.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | -6.40177% |
| 50-Day Moving Average | 9.33 |
| 200-Day Moving Average | 9.74 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zhejiang Ausun Pharmaceutical Co., Ltd. generated 784.77M in revenue and converted that into 196.30M in net income, yielding earnings per share of 0.23. EBITDA reached 181.66M, while operating income came in at 181.66M.
| Revenue | 784.77M |
| Gross Profit | 417.07M |
| Operating Income | 181.66M |
| Pretax Income | 227.31M |
| Net Income | 196.30M |
| EBITDA | 181.66M |
| EBIT | 181.66M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
Zhejiang Ausun Pharmaceutical Co., Ltd. holds 1.15B in cash and equivalents against 331.53M in total debt, resulting in a net debt position of -817.14M. Total book value stands at 1.87B, with working capital of 1.20B providing operational flexibility.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 331.53M |
| Net Debt | -817.14M |
| Equity (Book Value) | 1.87B |
| Book Value Per Share | 2.20 |
| Working Capital | 1.20B |
Cash Flow
After subtracting -110.16M in capital expenditures, free cash flow totaled -110.16M - equivalent to -0.13 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -110.16M |
| Free Cash Flow | -110.16M |
| FCF Per Share | -0.13 |
Margins
Zhejiang Ausun Pharmaceutical Co., Ltd. operates with a gross margin of 53.15, reflecting its pricing power and cost economics. The operating margin of 23.15 and net profit margin of 25.01 provide insight into operational efficiency.
| Gross Margin | 53.15 |
| Operating Margin | 23.15 |
| Pretax Margin | 28.97 |
| Profit Margin | 25.01 |
| EBITDA Margin | 23.15 |
Dividends & Yields
The company's payout ratio of 42.77 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.10 |
| Dividend Yield | N/A |
| Payout Ratio | 42.77 |
| Shareholder Yield | -0.06 |
| FCF Yield | 1.48 |
Stock Splits
Zhejiang Ausun Pharmaceutical Co., Ltd.'s most recent stock split took place on July 12, 2024 with a 5:7 split ratio.
| Last Split Date | 7/12/2024 |
| Split Ratio | 5:7 |
Scores
Zhejiang Ausun Pharmaceutical Co., Ltd. posts an Altman Z-Score of 7.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.72 |